A Randomised, Double-blind, Dose Finding, Repeat Dose Phase II Multicentre Study of ODX for the Treatment of Patients With Castration Resistant Prostate Cancer (CRPC) and Skeletal Metastases

Trial Profile

A Randomised, Double-blind, Dose Finding, Repeat Dose Phase II Multicentre Study of ODX for the Treatment of Patients With Castration Resistant Prostate Cancer (CRPC) and Skeletal Metastases

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Alendronic acid/guanidine dextran conjugate (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors DexTech Medical
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 1 Apr 2019 to 1 Oct 2019.
    • 25 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top